DDNews

DDNews is a monthly publication focused on the latest developments in technology and business within the pharmaceutical and biotechnology sectors. While many in the industry, including friends and competitors, offered their best wishes, we could sense their skepticism: "Good luck with that!" The market for drug discovery publications was quite competitive. However, as time passed, numerous other publications either merged, shut down, or reduced their offerings, while DDNews remained committed to enhancing our services for our readers.

International, National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#741618

United States

#302678

Health/Biotechnology and Pharmaceuticals

#248

Traffic sources

Monthly visitors

Articles

Epigenetic editing expands the reach of gene therapy

3 weeks ago | drugdiscoverynews.com | Allison Whitten

Rather than permanently cutting DNA, this new kind of gene therapy instead aims to regulate gene expression using epigenetic mechanisms. Credit: iStock.com/OseloteRather than permanently cutting DNA, this new kind of gene therapy instead aims to regulate gene expression using epigenetic mechanisms. | 6 min readAllison Whitten, PhDRegister for free to listen to this articleGene editing therapies are designed to be a one-and-done fix that cure a genetic disease and last a lifetime.
Optimizing spatial proteomics workflows for discovery and translation

1 month ago | drugdiscoverynews.com | Bree Coven Foster

Spatial proteomics is a powerful tool in biomedical research, enabling scientists to study the spatial distribution of proteins within tissues to gain deeper insights into cellular function and disease mechanisms. By mapping protein expression and localization in situ, spatial proteomics can reveal critical information about tumor microenvironments, immune cell interactions, and treatment responses that traditional bulk analyses cannot capture.
New cancer fitness drugs aim to trigger tumor death

1 month ago | drugdiscoverynews.com | Stephanie DeMarco

While oncogenes are notorious for causing cancer when mutated, they are not the only genes that keep cancer alive and spreading. Cancer fitness genes don’t cause cancer, but they help cancer cells avoid death through a variety of different mechanisms including by keeping oncogenes functioning, promoting certain signaling pathways, or sustaining an immunosuppressive environment around the tumor.
Designing for disruption in the pharmaceutical supply chain

1 month ago | drugdiscoverynews.com | Bree Coven Foster

Pharmaceutical companies are investing in supply chain visibility, ethical sourcing, and proactive strategies to build resilience and protect patient access. CREDIT: iStock.com/Pla2naPharmaceutical companies are investing in supply chain visibility, ethical sourcing, and proactive strategies to build resilience and protect patient access.
Building a smarter, more resilient medication supply chain

1 month ago | drugdiscoverynews.com | Bree Coven Foster

The pharmaceutical supply chain is under significant pressure, driven by escalating U.S. tariffs and global trade tensions. Recent policy shifts, including a 10 percent universal import tariff and proposed tariffs on foreign made pharmaceuticals, are disrupting sourcing strategies, increasing costs, and threatening the availability of essential medications.
To fight HIV, antibodies boost the immune system

1 month ago | drugdiscoverynews.com | Allison Whitten

HIV is incurable because it hides in latently infected cells. Researchers are hoping to change that — and prevent new infections — with the use of antibodies. HIV is incurable because it hides in latently infected cells. Researchers are hoping to change that — and prevent new infections — with the use of antibodies. | 8 min readAllison Whitten, PhDRegister for free to listen to this articleOnce the human immunodeficiency virus (HIV) enters a cell, there is no going back.
Targeting solid tumors two ways with one cancer vaccine

1 month ago | drugdiscoverynews.com | Stephanie DeMarco

In their quest to proliferate and spread, cancer cells will do anything they can to avoid being killed. Most often they develop mechanisms to suppress attacks by their would-be killers — immune cells. One way researchers and clinicians fight back against this suppression is with cancer vaccines that help immune cells recognize and attack cancer cells. But recognizing tumor cells is just one half of the equation.
Making mass spectrometry more accessible with automation

1 month ago | drugdiscoverynews.com | Stephanie DeMarco

Whether identifying metabolic dysfunction in a newborn baby or the levels of a drug in a person enrolled in a clinical trial, mass spectrometry can provide a window into how individual molecules pulsing through the body affect health. While mass spectrometry is a very sensitive analytical technique, it is a complex procedure to perform. The traditional mass spectrometry workflow often requires a series of manual and complicated steps to prepare samples before they even reach the mass spectrometer.
Developing drugs faster with flycode antibody tags

1 month ago | drugdiscoverynews.com | Jennifer Tsang

In the search for promising drug candidates that will make their way to approval, drug developers sift through thousands of molecules to find the best one for clinical trials. To narrow it down, part of the process involves tracking where the drugs go in the body and how long they stay there. For small molecule drugs, there are ways to test multiple drug candidates within the same mouse. But scientists must test therapeutic antibody drugs exhaustively one at a time in mice.
A new Parkinson’s disease treatment that adapts to the brain

1 month ago | drugdiscoverynews.com | Allison Whitten

The hallmark symptoms of Parkinson’s disease — shaky hands, muscle stiffness, slowed movements, and difficulty with balance — signify underlying irreversible damage to dopaminergic neurons in the brain. “Unfortunately, there is no cure for Parkinson's, and there are no disease-modifying therapies — meaning our treatments are only symptomatic,” said Suneil Kalia, a neurosurgeon and neuroscientist at the University of Toronto.